LIP
VRTX icon

Liontrust Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Liontrust Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6M Buy
25,460
+11,769
+86% +$5.22M 0.19% 79
2026
Q1 		$6.11M Sell
13,691
-1,355
-9% -$632K 0.1% 113
2025
Q4 		$6.82M Sell
15,046
-15,254
-50% -$6.57M 0.1% 127
2025
Q3 		$11.9M Buy
30,300
+3,346
+12% +$1.4M 0.17% 94
2025
Q2 		$12M Buy
26,954
+12,911
+92% +$5.95M 0.17% 91
2025
Q1 		$6.81M Sell
14,043
-3,986
-22% -$1.86M 0.11% 114
2024
Q4 		$7.26M Buy
18,029
+2,029
+13% +$941K 0.11% 112
2024
Q3 		$7.5M Hold
16,000
– – 0.11% 105
2024
Q2 		$7.5M Buy
16,000
+3,500
+28% +$1.52M 0.11% 105
2024
Q1 		$5.23M Sell
12,500
-500
-4% -$211K 0.07% 125
2023
Q4 		$5.29M Buy
+13,000
New +$4.8M 0.08% 117
2023
Q2 		– Sell
-2,955
Closed -$931K – 219
2023
Q1 		$931K Buy
+2,955
New +$886K 0.01% 179
2022
Q4 		– Sell
-10,640
Closed -$3.08M – 246
2022
Q3 		$3.08M Hold
10,640
– – 0.05% 167
2022
Q2 		$3M Buy
+10,640
New +$2.85M 0.04% 177

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Liontrust Investment Partners's VRTX Position: Q2 2026 in Review

Liontrust Investment Partners increased its Vertex Pharmaceuticals (VRTX) stake by 86% in Q2 2026, buying an estimated $5.22M and bringing the position to 25,460 shares worth $12.6M. The position accounts for 0.19% of the portfolio, ranked #79.

Liontrust Investment Partners first reported a position in VRTX in Q2 2022 and has held it in 14 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Liontrust Investment Partners held 25,460 shares of Vertex Pharmaceuticals worth $12.6M as of Q2 2026.
  • Liontrust Investment Partners bought 11,769 Vertex Pharmaceuticals shares in Q2 2026, an estimated $5.22M.
  • Vertex Pharmaceuticals made up 0.19% of Liontrust Investment Partners's portfolio in Q2 2026, its #79 holding.
  • Liontrust Investment Partners first reported a position in Vertex Pharmaceuticals in Q2 2022 and has held it in 14 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Liontrust Investment Partners's 13F filing for Q2 2026, filed 18 Aug 2026.